Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment: 2010-2016

Historic Asset Writedowns and Impairment for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2016 value amounting to $148,000.

  • Lineage Cell Therapeutics' Asset Writedowns and Impairment was N/A to $148,000 in Q4 2016 from the same period last year, while for Dec 2016 it was $559,000, marking a year-over-year change of. This contributed to the annual value of $950,000 for FY2016, which is N/A change from last year.
  • Lineage Cell Therapeutics' Asset Writedowns and Impairment amounted to $148,000 in Q4 2016, which was down 66.96% from $448,000 recorded in Q3 2016.
  • Over the past 5 years, Lineage Cell Therapeutics' Asset Writedowns and Impairment peaked at $448,000 during Q3 2016, and registered a low of -$25,000 during Q4 2014.
  • Over the past 2 years, Lineage Cell Therapeutics' median Asset Writedowns and Impairment value was $10,500 (recorded in 2014), while the average stood at $96,667.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Asset Writedowns and Impairment was 1,628.17% (2014), while the steepest drop was 20,933.33% (2014).
  • Quarterly analysis of 4 years shows Lineage Cell Therapeutics' Asset Writedowns and Impairment stood at $14,684 in 2012, then crashed by 99.18% to $120 in 2013, then tumbled by 20,933.33% to -$25,000 in 2014, then reached $148,000 in 2016.
  • Its Asset Writedowns and Impairment stands at $148,000 for Q4 2016, versus $448,000 for Q3 2016 and -$25,000 for Q4 2014.